Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Lithium Controls Central Nervous System Autoimmunity through Modulation of IFN-γ Signaling.
Chemotactic Cytokines: Gordon Research Conference on Molecular and Cellular Mechanisms in Health and Disease
Multiple sclerosis and chronic progressive external ophthalmoplegia associated with a large scale mitochondrial DNA single deletion.
Genzyme Announces EMA Accepts Oral Teriflunomide Marketing Application for Treatment of Multiple Sclerosis
Identical lesion morphology in primary progressive and relapsing-remitting MS -an ultrahigh field MRI study.
A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis.
45th European Brain and Behaviour Society Meeting
Myelin-specific Th17 cells induce severe relapsing optic neuritis with irreversible loss of retinal ganglion cells in C57BL/6 mice.
Are natural killer cells involved in multiple sclerosis etiology? Evidences from NKp46/NCR1 receptor modulation in an observational study.
Immune competence after alemtuzumab treatment of multiple sclerosis.
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.
G protein-coupled receptor 37 is a negative regulator of oligodendrocyte differentiation and myelination.
Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis.
Remote Physical Activity Monitoring in Neurological Disease: A Systematic Review.
Adaptive autoimmunity and Foxp3-based immunoregulation in zebrafish.
Beginning of the end of two-stage theory purporting that inflammation then degeneration explains pathogenesis of progressive multiple sclerosis.
Rapid exacerbation of neuromyelitis optica after rituximab treatment.
Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension study.
Antioxidant properties of the triaminopyridine, flupirtine.
Interferon-beta in pediatric multiple sclerosis patients: safety in short-term prescription.
Studying both sexes: a guiding principle for biomedicine.
Individualized quality of life of severely affected multiple sclerosis patients: practicability and value in comparison with standard inventories.
Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders.
Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.
Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.

Pages